Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced that it has received Gets EUA Endorsement and Import License from Mexico Authority COFEPRIS for COVI-STIX™. COVI-STIX is a subtle and quick investigative examination for the uncovering of the SARS-CoV-2 disease. COFEPRIS delivered an Emergency Use Authorization (EUA) authorization and an import
license for COVI-STIX on June 14, 2021.
Company to establish Sorrento Mexico Ltd
The company has decided to form Sorrento Mexico Ltd, a subsidiary company, to accomplish commercial operations in Mexico following its receipt of the EUA approval from COFEPRIS under registration number “OFICIO: CAS/10720/2021”. Sorrento will commercially launch the COVI-STIX examination in Mexico, with the first deliveries projected to be transported in July.
Company Reaches Multi-Year Supportive Investigation and Development Agreement with the U.S. Naval Medical Research Unit
In other news, the company revealed that it had reached a Multi-Year Cooperative Research and Development Agreement with the U.S. Naval Medical Research Unit. Under the expressions of the agreement, NAMRU-3 will carry out an investigation and scientific authentication investigation. At the same time, Sorrento will offer practical know-how and access to its collection of products to fight the SARS-CoV-2 and intimidations developing due to variations of worry.
The task of NAMRU-3 is to safeguard warfighter readiness through perceiving, discouraging, and reacting to infectious illness intimidations through assimilation with associates through U.S. Africa Command (AFRICOM), Central Command (CENTCOM), and European Command (EUCOM) zones of accountability. The purpose of this partnership is to execute infectious disease investigation that directs the Department of Defense (DoD), notifies public health policy of host nation associates, and advances medical promptness of the U.S. Armed Forces across NAMRU-3 areas of accountability. Through collective resources and logistical support, the complete aim of this research collaboration will be to manage investigation on existing, evolving, and re-emerging infectious illnesses. It will also improve Force Health Protection and deliver acute records concerning countermeasures to alleviate infectious disease diffusion, including scrutiny and product expansion.
“We are excited about this opening to cooperate with NAMRU-3 to quickly and professionally assess and position our yields in parts of the domain where more operative solutions are frantically required.” – Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics.